Opdyta 40mg Injection

Introduction

Opdyta is a prescription medication that contains the active ingredient Nivolumab. It is also known by its generic name. Opdyta is primarily used for the treatment of certain types of cancer.

Uses

Opdyta is commonly prescribed for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma. It is used when the cancer has spread or cannot be surgically removed. Opdyta works by helping the immune system recognize and attack cancer cells.

Dosage and Administration

The dosage of Opdyta will vary depending on the specific type of cancer being treated and other individual factors. It is typically administered by a healthcare professional as an intravenous infusion. The infusion is usually given over a period of time, which can range from 30 minutes to several hours. The exact dosage and administration schedule will be determined by your healthcare provider.

Mechanism of Action

Nivolumab, the active ingredient in Opdyta, belongs to a class of medications called immune checkpoint inhibitors. It works by blocking a protein called PD-1 on immune cells, which helps to activate the immune system’s response against cancer cells. By doing so, Opdyta helps the immune system to recognize and attack cancer cells more effectively.

Side Effects

Common side effects may include fatigue, nausea, loss of appetite, diarrhea, rash, and itching. These side effects are typically mild to moderate and usually improve over time. However, if you experience any severe or persistent side effects, contact your healthcare provider immediately.

Serious side effects of Opdyta can include immune-related side effects, such as inflammation of the lungs, liver, or colon. These side effects may cause symptoms such as shortness of breath, abdominal pain, or changes in bowel habits. If you experience any of these symptoms, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products, before starting Opdyta. Some medications may interact with Opdyta and affect its effectiveness or increase the risk of side effects. Your healthcare provider will review your medication list and determine if any adjustments are needed.

Precautions

Before using Opdyta, inform your healthcare provider about any medical conditions you have, including a history of immune system disorders, organ transplant, or autoimmune diseases. Opdyta may not be suitable for everyone, and your healthcare provider will assess the potential risks and benefits before prescribing it.

Avoid receiving live vaccines while using Opdyta, as it may interfere with the effectiveness of the vaccine. Additionally, Opdyta may cause fetal harm if used during pregnancy, so discuss any pregnancy plans or concerns with your healthcare provider.

Storage

Opdyta should be stored in a refrigerator between 2°C and 8°C (36°F and 46°F). It should be kept in its original packaging and protected from light. Do not freeze or shake the medication. If you have any questions about storage, consult your healthcare provider or pharmacist.

Patient Tips

• Attend all scheduled appointments for Opdyta administration and follow-up visits to monitor your response to treatment.
• Be sure to report any new or worsening symptoms to your healthcare provider, as they may be related to the medication or your underlying condition.
• Practice good hygiene and follow infection control measures to reduce the risk of infections while using Opdyta.
• Inform your healthcare provider if you develop any signs of an allergic reaction, such as hives, itching, or swelling, while using Opdyta.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• OPDIVO 10 mg/mL concentrate for solution for infusion (Health Professionals SmPC) Available at:
• Nivolumab (Drugs.com) [Accessed 11 Jun. 2024] (online) Available at:
• nivolumab 240 mg-relatlimab-rmbw 80 mg/20 ml intravenous solution (RX) [Accessed 24 Jun. 2024] (online) Available at:
• Nivolumab Injection (MedlinePlus) [Accessed 18 Jun. 2024] (online) Available at:
• Paik J. Nivolumab Plus Relatlimab: First Approval. Drugs. 2022 Jun;82(8):925-931. doi: 10.1007/s40265-022-01723-1. [Accessed 16 Jun. 2024] Available at: